Transplant

In instances when longer term treatment is required, continued use of IG should be based on objective measures of effectiveness established at the outset of treatment. These measures should be assessed no later than 6 months after initiation of treatment (unless specifically indicated) and at least annually thereafter. If clinical effectiveness has not been achieved, IG should be discontinued.

Community-acquired respiratory virus (CARV), upper respiratory tract infection (URTI) in high-risk patients

Recommended Indications in which IG can be used

Order Number: T1-CARV/URTI

Community-acquired respiratory virus (CARV), upper respiratory tract infection (URTI)

Do Not Use

Cytomegalovirus (CMV) infection, prevention

Do Not Use

Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorders (PTLD)

Do Not Use

Parvovirus B19 in solid organ transplant recipients – established infection

Recommended Indications in which IG can be used

Order Number: T2-PvB19

Parvovirus B19 in solid organ transplant recipients

Do Not Use

Pulmonary graft-versus-host disease

Do Not Use

Solid organ transplant, active antibody-mediated rejection (ABMR) prevention and management

Recommended Indications in which IG can be used

Order Number: T3-ABMR

Solid organ transplant, ongoing desensitization, prevention or treatment of graft rejection

Recommended Indications in which IG can be used

Order Number: T4-DGR